Title: Non-Phosphorous-Linked Oligomeric Compounds and Their Use in Gene Modulation. Number: 20050032067. Filed: Aug. 5, 2003. Lead Inventor: Thazha Prakash, Isis Pharmaceuticals (Alnylam Pharmaceuticals).
The patent application covers “oligomer compositions comprising first and second oligomers … wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer; at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid; and at least one of the first or second oligomers includes at least two nucleoside having a modified non-phosphorous-containing internucleoside linkage,” states its abstract. “Oligomer/protein compositions are also provided comprising an oligomer complementary to and capable of hybridizing to a selected target nucleic acid and at least one protein comprising at least a portion of an RNA-induced silencing complex, wherein at least two nucleosides of the oligomer has a modified non-phosphorous-containing internucleoside linkage.”
Title: Gene-Controlling Flowering Time of Plants and Method for Manipulating Flowering Time of Plant Using the Same. Number: 20050034194. Filed: Feb. 19, 2004. Lead Inventor: Jong Seob Lee, Seoul National University.
“The … invention relates to a gene controlling the flowering time of plants, and a method for manipulating the flowering time of plants using the gene,” the patent application’s abstract states. “More particularly, the present invention relates to a LOV1 gene controlling the flowering time of plants, which is isolated from Arabidopsis thaliana, and also to a method for either delaying the flowering time of plants by overexpressing the LOV1 gene in the plants, or inducing the early flowering of the plants by repressing the expression of the LOV1 gene in the plants.”
Title: Inhibition of Gene Function by Delivery of Polynucleotide-Based Gene Expression Inhibitors to Mammalian Cells In Vivo. Number: 20050037989. Filed: June 23, 2004. Lead Inventor: David Lewis, Mirus.
The patent application, its abstract states, covers “a process ... to deliver polynucleotide-based gene expression inhibitors to cells in a mammal in vivo for the purpose of inhibiting gene expression in the cells. Inhibition is sequence-specific and relies on sequence similarity of the polynucleotide-based gene expression inhibitor and the target nucleic acid molecule. Delivery of the polynucleotide-based gene expression inhibitor can enhance the efficacy of co-delivered small molecule drugs,” it adds.
Title: Methods and Compositions for Controlling Efficacy of RNA Silencing. Number: 20050037988. Filed: June 2, 2004. Lead Inventor: Phillip Zamore, University of Massachusetts.
“Based at least in part on an understanding of the mechanisms by which small RNAs (e.g., naturally occurring miRNAs) mediate RNA silencing in plants, rules have been established for determining, for example, the degree of complementarity required between an RNAi-mediating agent and its target, i.e., whether mismatches are tolerated, the number of mismatches tolerated, the effect of the position of the mismatches, etc.,” the patent application’s abstract states. “Such rules are useful, in particular, in the design of improved RNAi-mediating agents which allow for more exact control of the efficacy of RNA silencing.”
Title: Modulation of the RNA Interference Pathway. Number: 20050037387. Filed: May 24, 2004. Lead Inventor: Donna Ward, Isis Pharmaceuticals.
The patent application, its abstract states, cover “compounds, compositions and methods … for modulating the RNAi pathway. The compositions comprise oligonucleotides, targeted to nucleic acid molecules encoding EIF2C2.”
The abstract notes that the application also covers “methods of using these compounds for modulation of RNA interference as well as EIF2C2 expression and for diagnosis and treatment of disease associated with expression of EIF2C2,” as well as “compounds, compositions, and methods for modulating the expression of DDX36. The compositions comprise oligonucleotides, targeted to nucleic acid encoding DDX36.
“Methods of using these compounds for modulation of DDX36 expression and for diagnosis and treatment of diseases and conditions associated with expression of DDX36” are also covered, the abstract adds.
Title: Detection and Quantification of siRNA on Microarrays. Number: 20050037362. Filed: Aug. 11, 2003. Lead Inventor: Jose Remacle, Eppendorf Array Technologies.
“The … invention relates to a new method for the detection, identification, and/or quantification of multiple gene-specific siRNA or stRNA, respectively, the inducers of RNAi,” the patent application’s abstract states. “In particular the present invention relates to a method for detecting the presence or change in concentration of siRNA in a cell, which may be induced by environmental conditions.”